Strides Pharma Science's Q2 FY 2025-26 Quarterly Results

Result Summary

• Strides Pharma Science Ltd reported a 10.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 1.5%.
• Its expenses for the quarter were up by 8.7% QoQ and down 1.2% YoY.
• The net profit increased 24.6% QoQ and increased 40.4% YoY.
• The earnings per share (EPS) of Strides Pharma Science Ltd stood at 13.84 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Strides Pharma Science Ltd is a pharmaceutical company that focuses on the development, manufacture, and marketing of a wide range of generic pharmaceutical products. The company operates in the healthcare industry, providing essential medications across various therapeutic segments. Strides Pharma has a global presence, with a strong emphasis on regulated markets, and has been involved in several strategic initiatives to expand its portfolio and market reach. There is no specific recent major development available in the provided data.

Revenue

In Q2FY26, Strides Pharma Science Ltd reported a total income of ₹1,247.97 crores, marking an increase of 10.6% quarter-over-quarter (QoQ) from ₹1,128.32 crores in Q1FY26, and a modest year-over-year (YoY) growth of 1.5% from ₹1,229.52 crores in Q2FY25. The revenue growth demonstrates an upward trend in the company's income generation over the last quarter and a slight improvement over the same quarter in the previous year. The rise in total income reflects the company's ongoing ability to enhance its revenue base.

Profitability

The company achieved a profit before tax of ₹154.16 crores in Q2FY26, representing a 26.4% increase QoQ from ₹121.94 crores in Q1FY26 and a significant 20.7% increase YoY from ₹127.67 crores in Q2FY25. After accounting for taxes, the profit after tax stood at ₹131.52 crores, showing a 24.6% increase QoQ from ₹105.59 crores and a 40.4% rise YoY from ₹93.66 crores. The earnings per share for Q2FY26 were ₹13.84, compared to ₹10.81 in Q1FY26 and ₹10.12 in Q2FY25, indicating a rise of 28.0% QoQ and 36.8% YoY. The profitability metrics reveal robust growth in both pre-tax and post-tax figures.

Operating Metrics

The total expenses for Q2FY26 amounted to ₹1,085.03 crores, which is an 8.7% increase QoQ from ₹998.01 crores in Q1FY26 but a slight decline of 1.2% YoY from ₹1,097.97 crores in Q2FY25. The effective tax rate for the quarter was calculated based on the tax and profit before tax figures. The company's operational efficiency can be further analyzed through these figures, indicating the management of expenses relative to income and tax liabilities. The trends in expenses and effective tax rate provide insight into the company's operational cost management strategies over the periods in question.